Tag: OcuNexus Therapeutics
Eyevance bags global rights of ophthalmic drug Nexagon from OcuNexus
Eyevance Pharmaceuticals has acquired global licensing rights of ophthalmic drug Nexagon, a 30-base antisense oligomer, from OcuNexus Therapeutics which is being developed for the treatment ... Read More